Full-Time
Therapeutic Strategy Director
Obesity
IQVIA
10,001+ employees
Analytics and research for life sciences
Compensation Overview
$139.7k - $259.4k/yr
Expert
Company Historically Provides H1B Sponsorship
Durham, NC, USA
- Remain up to date with knowledge and information that supports effectiveness as a Therapeutic Strategy Lead e.g. understanding IQVIA’ services, tools and product offerings, status and trends in assigned TA(s), innovations and advances in clinical trial methodology, and business intelligence.
- Broad protocol and therapeutic knowledge
- Comprehensive global knowledge, awareness, and practical understanding of the biopharma industry, drug development lifecycle and operational clinical trial delivery
- Robust and current knowledge of scientific, clinical, regulatory, commercial and competitive landscape in applicable therapeutic area
- Strong leadership skills, ability to work with minimal supervision, and lead a virtual team in a matrix organization.
- Flexible and able to work in situations where specifications may or may not be well defined and willing to support work in other therapeutic areas when required
- Confident and capable in the use of technology, applications, and other media e.g. databases and internet to research new opportunities, maintain currency of therapeutic and operational knowledge, and competitive landscape.
- Leverage IQVIA medical, scientific, operational and data science experts to determine the optimal solution, project design and lead a cross-functional team in proposal development through to award
- Assigned to take ownership of developing client-centric solutions, designing both strategic and methodological approaches to ensure that IQVIA secures client projects
- Champion and advocate the CORE-powered solutions and include existing and new innovative solutions as applicable and appropriate through the sales process. This may include, but is not limited to, stand-alone programs and projects, requests for information (RFI), capabilities, and early engagement.
- As a leader of the pre-award strategy team, the TSL is accountable and responsible for creation of innovative, effective, and compelling therapeutic and operational strategies that client differentiate IQVIA from its competitors.
- Work with key internal stakeholders and pre/post-award teams to analyze information and data that enables development of efficient and feasible delivery solutions. This may include, but is not limited to, protocol feasibility and risk management, assessment and management of the competitive landscape, optimal country and site distributions, site and patient recruitment strategies, monitoring and vendor strategies.
- Actively support Sales in the preparation and conduct of client and bid defense meetings e.g. training and preparation of the assigned project team; provide specific content; ensure presentation focus and content effectively conveys project strategy and critical win themes. Attend and present at client meetings, or bid defense meetings, as required, (based on the strategy for selling the opportunity).
- Translate the sold strategy to the delivery team and be an available resource for the delivery team when changes to strategy are required.
- Provide post award strategy guidance and support to delivery teams if in-flight studies require changes to strategy.
- Bachelor's degree in life sciences, advanced degree preferred, with extensive knowledge of Internal Medicine and 10+ years’ global clinical research experience, including hands on Phase I operational delivery and/or drug development experience. Proven track record in operational delivery and/or drug development; or equivalent combination of education, training and experience.
- Must have extensive experience with Clinical Operations and Clinical Project Management.
IQVIA provides advanced analytics, technology solutions, and clinical research services specifically for the life sciences industry. Their main offering, IQVIA Connected Intelligence™, utilizes large datasets and technology to deliver quick insights that help clients speed up the development and marketing of new medical treatments. This service is designed to improve healthcare outcomes by connecting various aspects of healthcare. IQVIA stands out from its competitors by focusing on patient privacy, employing advanced technologies to protect individual data. The company's goal is to enhance understanding of diseases and human behavior, ultimately contributing to the development of cures in healthcare.
Company Size
10,001+
Company Stage
IPO
Headquarters
Durham, North Carolina
Founded
1998
Simplify's Take
What believers are saying
- IQVIA is recognized as a leader in decentralized clinical trial technologies.
- The launch of Site Lab Navigator automates and streamlines clinical trial processes.
- IQVIA's focus on equitable healthcare access can influence policy and improve systems.
What critics are saying
- Public scrutiny of profit-driven healthcare models may impact IQVIA's reputation.
- CAR T-cell therapy access disparities could lead to regulatory scrutiny in Europe.
- IQVIA's $2 billion senior notes offering increases financial risk if market conditions change.
What makes IQVIA unique
- IQVIA's Connected Intelligence™ offers rapid insights for clinical development and commercialization.
- The company is a leader in protecting individual patient privacy with advanced technologies.
- IQVIA's Med-R1 8B LLM outperforms larger models in medical reasoning.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Life Insurance
Flexible Work Hours
Paid Vacation
Wellness Program
401(k) Retirement Plan
Company News
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) today announced that its wholly-owned subsidiary, IQVIA Inc. (the “Issuer”), priced an offering of $2,000,000,000 in...
<p> <strong>RESEARCH TRIANGLE PARK, N.C.</strong> – IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) today announced that its wholly-owned subsidiary, IQVIA Inc. (the “Issuer”), intends to raise $2,000,000,000 through an offering of senior notes due 2032 (the “Notes”). </p> <p> The proceeds from the Notes offering will be used to repay existing borrowings under the Issuer’s revolving credit facility and to pay fees and expenses related to the Notes offering, with any excess proceeds used for other general corporate purposes. The consummation of the Notes offering is subject to market and other customary conditions. </p> <p> This press release does not constitute an offer to sell or the solicitation of an offer to buy the Notes, nor shall there be any offer, solicitation or sale of the Notes in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful. The Notes to be offered have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or the securities laws of any other jurisdiction and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act. The Notes are being offered only to persons reasonably believed to be qualified institutional buyers in the United States in reliance on Rule 144A under the Securities Act and outside the United States only to non-U.S. investors pursuant to Regulation S under the Securities Act. Any offer of the Notes will be made only by means of a private offering memorandum. </p> <br /> <h5> About IQVIA </h5> <p> IQVIA (NYSE:IQV) is a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. IQVIA’s portfolio of solutions are powered by IQVIA Connected Intelligence™ to deliver actionable insights and services built on high-quality health data, Healthcare-grade AI™, advanced analytics, the latest technologies and extensive domain expertise. IQVIA is committed to using artificial intelligence responsibly, with AI-powered capabilities built on best-in-class approaches to privacy, regulatory compliance and patient safety, and delivering AI to the high standards of trust, scalability and precision demanded by the industry. With approximately 89,000 employees in over 100 countries, including experts in healthcare, life sciences, data science, technology and operational excellence, IQVIA is dedicated to accelerating the development and commercialization of innovative medical treatments to help improve patient outcomes and population health worldwide. </p> <p> IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures. </p> <br /> <h5> Forward Looking Statements </h5> <p> Certain statements in this press release are forward-looking statements. These statements involve a number of risks, uncertainties and other factors, including the failure to consummate the Notes offering, and potential changes in market conditions that could cause actual results to differ materially. </p> <br /> <h5> IQVIAFIN </h5> <p> Kerri Joseph, IQVIA Investor Relations (<a href="mailto:[email protected]">[email protected]</a>)<br /> +1.973-541-3558 </p>
New National Campaign Confronts the Healthcare Industry's Perverse Incentives and Sparks a Movement for Preventive WellnessNEW YORK, May 19, 2025 /PRNewswire/ -- Vimergy, the premium supplement company helping people reclaim their health with pure, potent, and timeless products, today launched the "Mouth of America" – an immersive national campaign debuting a large-scale art installation in New York City. Designed to provoke and inspire, the campaign calls attention to America's real health crisis: chronic, system-driven illness fueled by a healthcare model that profits when we stay sick. This problem shows no sign of abating: In 2024, Americans collectively took 215 billion doses of prescription medication
NEW IQVIA INSTITUTE REPORT WARNS OF ACCESS DISPARITIES FORCAR T-CELL THERAPY ACROSS EUROPEStockley Park, UK – 23 April 2025 – A new report reveals disparities in chimeric antigen receptor (CAR) T-cell therapy delivery across Europe, with healthcare system utilisation rates of the therapy as low as 11% for eligible patients. The independent research ‘Achieving CAR T-Cell Therapy Health System Readiness: An assessment of barriers and opportunities’ by the IQVIA Institute for Human Data Science, funded by Gilead and Kite, highlights challenges across countries that can lead to uneven access to CAR T-cell therapy. The report, which assessed seven countries (Australia, Canada, France, Germany, Italy, Spain, the United Kingdom), found that factors such as complex referral pathways, limited treatment centers and reimbursement challenges are hindering access to this potentially life-saving treatment for eligible patients."CAR T-cell therapy, a potentially curative treatment that has been available since 2017, has transformed the lives of thousands of people worldwide," says Murray Aitken, Executive Director, IQVIA Institute for Human Data Science. "Despite the progress, access barriers still remain for patients eligible for CAR T-cell therapy, leading to worrying inequities in care across Europe. The Institute’s report stresses the need for policy action to address these disparities, help people access this innovative treatment and improve patient outcomes."The IQVIA Institute shares key policy recommendations to support equitable patient access across healthcare systems. These include:1Establish standardised governance systems to coordinate care between referring and treating centres: Patient referrals continue to be a major challenge across countries, with 61% of referring physicians in Spain citing this as a main barrier to treatment.Develop plans to regularly monitor progress and timely access to CAR T-cell therapy: Long-term assessment and monitoring are required to address low utilisation rates across countries, with France delivering the highest percentage of eligible patients receiving treatment at only 30%.Long-term assessment and monitoring are required to address low utilisation rates across countries, with France delivering the highest percentage of eligible patients receiving treatment at only 30%
LAKEWOOD, Colo., April 16, 2025 /PRNewswire/ - Terumo Blood and Cell Technologies (Terumo BCT), a medical technology company, today announced the addition of Patrick Daly as its Chief Business Officer as the company continues to expand its capabilities to meet evolving market segments.